New gene therapy injection aims to boost prostate cancer radiation results

NCT ID NCT07332000

Recruiting now Disease control Sponsor: Candel Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a gene therapy called aglatimagene besadenovec, given with valacyclovir, in 45 men with intermediate-risk prostate cancer who will also receive radiation. The main goal is to see how the therapy spreads in the body and to measure immune responses and tumor markers like PSA. Participants must be planning radiation and able to tolerate prostate injections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALIZED INTERMEDIATE-RISK PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adenocarcinoma prostate cancer prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER (ADENOCARCINOMA) PROSTATE CANCER PATIENTS TREATED BY RADIOTHERAPY

Contacts and locations

Locations

Academic Urology and Urogynecology of Arizona
RECRUITING

Peoria, Arizona, 85381, United States
Chesapeake Urology Research Associates
RECRUITING

Towson, Maryland, 21204, United States
Colorado Clinical Research
RECRUITING

Lakewood, Colorado, 80228, United States
START Carolinas
RECRUITING

Myrtle Beach, South Carolina, 29572, United States
Sheldon Freedman, MD Ltd.
RECRUITING

Las Vegas, Nevada, 89144, United States
Summit Health
RECRUITING

Saddle Brook, New Jersey, 07663, United States
Urology Associates
RECRUITING

Littleton, Colorado, 80122, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.